AKE:EURONEXT PARISArkema SA Analysis

Akebia Therapeutics (AKE) is trading at $1.46, well below its 20‑day ($1.27), 50‑day ($1.37) and 200‑day ($2.48) simple moving averages, signaling a bearish price environment. The Relative Strength Index sits at 60.7, edging into overbought territory but not yet extreme. A bullish MACD histogram (+0.03) and a MACD line crossing above its signal line suggest short‑term momentum may be turning positive. Volume has been on a downward trend, and the 30‑day realized volatility exceeds 75%, highlighting a highly erratic trading pattern. The stock’s beta of roughly 0.8 indicates modest sensitivity to broader market moves, while the current price is perched near the technical support of $1.14 and faces resistance around $1.52.
On the fundamentals side, revenue grew 24% year‑over‑year to $236 million with an impressive 83% gross margin, yet operating and net margins remain negative (‑10.5% and ‑2.3% respectively). The company generated $68 million of free cash flow and holds $185 million in cash against $199 million of debt, leaving a modest net‑debt position. A discounted cash‑flow model values the business at roughly $9.11 per share, implying a potential upside of over 200% from today’s price. Recent earnings disclosed a $12.2 million Q4 loss and flat demand for its lead product Vafseo, underscoring short‑term earnings pressure. Nonetheless, the pipeline of AKB‑9090 and AKB‑10108, plus licensing agreements in Asia, provides a credible growth narrative that aligns with the analyst consensus of a “strong buy.”